Now Is A Suitable Moment For A Long-Term Purchase Of BioXcel Therapeutics Inc (NASDAQ: BTAI)

Currently, there are 28.15M common shares owned by the public and among those 20.68M shares have been available to trade.

Insiders at the company have transacted a total of 42 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 23 of these insider trades were purchases, accounting for 233,160 shares. Insider sales of the common stock occurred on 19 occasions, with total insider shares sold totaling 202,649 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

However, the script later moved the day high at 2.7800, down -43.73%. The company’s stock has a 5-day price change of -31.05% and -54.72% over the past three months. BTAI shares are trading -28.47% year to date (YTD), with the 12-month market performance down to -93.65% lower. It has a 12-month low price of $2.23 and touched a high of $34.12 over the same period. BTAI has an average intraday trading volume of 9.76 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -31.73%, -33.23%, and -75.14% respectively.

Institutional ownership of BioXcel Therapeutics Inc (NASDAQ: BTAI) shares accounts for 34.78% of the company’s 28.15M shares outstanding.

It has a market capitalization of $63.15M and a beta (3y monthly) value of 0.37. The earnings-per-share (ttm) stands at -$7.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 21.04% over the week and 9.99% over the month.

Analysts forecast that BioXcel Therapeutics Inc (BTAI) will achieve an EPS of -$0.91 for the current quarter, -$1.02 for the next quarter and -$2.56 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.23 while analysts give the company a high EPS estimate of -$0.61. Comparatively, EPS for the current quarter was -$1.95 a year ago. Earnings per share for the fiscal year are expected to decrease by -3.65%, and 61.41% over the next financial year.

Looking at the support for the BTAI, a number of firms have released research notes about the stock. Mizuho stated their Neutral rating for the stock in a research note on August 15, 2023, with the firm’s price target at $40-$4.

Most Popular

Related Posts